Skip to main content
. Author manuscript; available in PMC: 2012 Dec 8.
Published in final edited form as: Cancer Lett. 2011 Aug 6;311(2):219–229. doi: 10.1016/j.canlet.2011.07.023

Figure 1. Drug concentrations after the concurrent treatment schedule.

Figure 1

Panel A is the treatment schedule with irinotecan alone or in concurrent with MSC.

Panel B is plasma irinotecan or SN-38 concentrations 2h after treatment with 100mg/kg irinotecan alone or after the concurrent combination treatment with MSC (0.2 mg/d) and irinotecan.

Panel C is the irinotecan or SN-38 concentration in A253 or FaDu 2h after treatment with 100mg/kg irinotecan alone or in concurrent combination with MSC (0.2 mg/d).

The figure shows no significant difference in drug concentration after the concurrent combination treatment when compared with irinotecan alone.